Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company, develops pharmacological treatments for substance use, addictive and eating disorders. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes treatments for eating disorders, including bulimia nervosa and binge eating disorders, alcohol use disorders, a long term treatment to prevent relapse for patients with opioid use disorders, cocaine use disorders, and a heroin vaccine. Opiant Pharmaceuticals, Inc. has a collaboration agreement with Titan Pharmaceuticals, Inc. to explore development of a novel approach to the prevention of opioid relapse and overdose in individuals with opioid use disorder. The company was formerly known as Lightlake Therapeutics Inc. and changed its name to Opiant Pharmaceuticals, Inc. in January 2016. Opiant Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Santa Monica, California. Opiant Pharmaceuticals, Inc. is a subsidiary of Pelikin Group.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Metal mining
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:OPNT
CUSIPN/A
Phone310-598-5410
Debt
Debt-to-Equity RatioN/A
Current Ratio3.41
Quick Ratio3.41
Price-To-Earnings
Trailing P/E Ratio5.34
Forward P/E Ratio-2.68
P/E GrowthN/A
Sales & Book Value
Annual Sales$18.45 million
Price / Sales2.40
Cash Flow$3.3074 per share
Price / Cash4.75
Book Value$0.02 per share
Price / Book785.50
Profitability
EPS (Most Recent Fiscal Year)$2.94
Net Income$6.58 million
Net Margins-449.52%
Return on Equity-471.43%
Return on Assets-190.80%
Miscellaneous
Employees11
Outstanding Shares2,820,000
Market Cap$42.65 million
Opiant Pharmaceuticals (NASDAQ:OPNT) Frequently Asked Questions
What is Opiant Pharmaceuticals' stock symbol?
Opiant Pharmaceuticals trades on the NASDAQ under the ticker symbol "OPNT."
How were Opiant Pharmaceuticals' earnings last quarter?
Opiant Pharmaceuticals Inc (NASDAQ:OPNT) released its earnings results on Thursday, August, 9th. The technology company reported ($0.52) earnings per share for the quarter, beating the Zacks' consensus estimate of ($1.07) by $0.55. The technology company had revenue of $3.15 million for the quarter, compared to analysts' expectations of $2.10 million. Opiant Pharmaceuticals had a negative net margin of 449.52% and a negative return on equity of 471.43%. View Opiant Pharmaceuticals' Earnings History.
What price target have analysts set for OPNT?
1 analysts have issued 12-month price targets for Opiant Pharmaceuticals' shares. Their forecasts range from $32.00 to $32.00. On average, they anticipate Opiant Pharmaceuticals' stock price to reach $32.00 in the next year. This suggests a possible upside of 103.7% from the stock's current price. View Analyst Price Targets for Opiant Pharmaceuticals.
What is the consensus analysts' recommendation for Opiant Pharmaceuticals?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Opiant Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Opiant Pharmaceuticals.
Who are some of Opiant Pharmaceuticals' key competitors?
Some companies that are related to Opiant Pharmaceuticals include Amerigo Resources (ARREF), Wealth Minerals (WMLLF), Jaguar Mining (JAGGF), Rubicon Minerals (RBYCF), Alderon Iron Ore (AXXDF), Santa Fe Gold (SFEG), Silver Bull Resources (SVBL), Trident Brands (TDNT), Atlatsa Resources (ATLRF), Quantum Materials (QTMM), Westwater Resources (WWR), Bunker Hill Mining (BHLL), Avalon Advanced Materials (AVLNF), Pacific Booker Minerals (PBMLF) and Quaterra Resources (QTRRF).
Who are Opiant Pharmaceuticals' key executives?
Opiant Pharmaceuticals' management team includes the folowing people:
- Dr. Roger Crystal, CEO & Director (Age 42)
- Mr. Kevin Andrew Pollack Esq., J.D., M.B.A., Advisor (Age 48)
- Mr. David D. O'Toole, CFO & Director (Age 59)
- Dr. Phil Skolnick, Chief Scientific Officer (Age 71)
- Mr. Quan Vu, VP of Corp. Devel.
Has Opiant Pharmaceuticals been receiving favorable news coverage?
News headlines about OPNT stock have been trending somewhat positive this week, according to Accern Sentiment. The research firm identifies positive and negative media coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Opiant Pharmaceuticals earned a media and rumor sentiment score of 0.23 on Accern's scale. They also assigned headlines about the technology company an impact score of 47.06 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near future. View Recent Headlines for Opiant Pharmaceuticals.
How do I buy shares of Opiant Pharmaceuticals?
Shares of OPNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Opiant Pharmaceuticals' stock price today?
One share of OPNT stock can currently be purchased for approximately $15.71.
How big of a company is Opiant Pharmaceuticals?
Opiant Pharmaceuticals has a market capitalization of $42.65 million and generates $18.45 million in revenue each year. The technology company earns $6.58 million in net income (profit) each year or $2.94 on an earnings per share basis. Opiant Pharmaceuticals employs 11 workers across the globe.
How can I contact Opiant Pharmaceuticals?
Opiant Pharmaceuticals' mailing address is 201 SANTA MONICA BOULEVARD SUITE 500, SANTA MONICA CA, 90401. The technology company can be reached via phone at 310-598-5410 or via email at [email protected]
MarketBeat Community Rating for Opiant Pharmaceuticals (NASDAQ OPNT)
MarketBeat's community ratings are surveys of what our community members think about Opiant Pharmaceuticals and other stocks. Vote "Outperform" if you believe OPNT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OPNT will underperform the S&P 500 over the long term. You may vote once every thirty days.
